{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:34:16Z","timestamp":1793046856097,"version":"4.5.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T00:00:00Z","timestamp":1364256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40272-013-0018-4","type":"journal-article","created":{"date-parts":[[2013,3,25]],"date-time":"2013-03-25T10:14:10Z","timestamp":1364206450000},"page":"191-202","source":"Crossref","is-referenced-by-count":55,"title":["Premenstrual Dysphoric Disorder and Severe Premenstrual Syndrome in Adolescents"],"prefix":"10.1007","volume":"15","author":[{"given":"Andrea J.","family":"Rapkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Mikacich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,26]]},"reference":[{"issue":"9619","key":"18_CR1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0140-6736(08)60527-9","volume":"371","author":"KA Yonkers","year":"2008","unstructured":"Yonkers KA, O\u2019Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008;371(9619):1200\u201310.","journal-title":"Lancet"},{"issue":"2","key":"18_CR2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/erp.09.14","volume":"9","author":"AJ Rapkin","year":"2009","unstructured":"Rapkin AJ, Winer SA. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness. Expert Rev Pharmacoecon Outcomes Res. 2009;9(2):157\u201370.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"18_CR3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/jwh.2010.2161","volume":"20","author":"EW Freeman","year":"2011","unstructured":"Freeman EW, Halberstadt SM, Rickels K, et al. Core Symptoms that discriminate premenstrual syndrome. J Women\u2019s Health. 2011;20:29\u201335.","journal-title":"J Women\u2019s Health"},{"key":"18_CR4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/09513590601167969","volume":"23","author":"U Halbreich","year":"2007","unstructured":"Halbreich U, Backstrom T, Eriksson E, et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol. 2007;23:123\u201330.","journal-title":"Gynecol Endocrinol"},{"key":"18_CR5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/14656566.9.3.429","volume":"9","author":"AJ Rapkin","year":"2008","unstructured":"Rapkin AJ, Winer SA. The pharmacologic management of premenstrual dysphoric disorder. Exper Opin Pharmacother. 2008;9:429\u201345.","journal-title":"Exper Opin Pharmacother"},{"key":"18_CR6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/15246090050147736","volume":"9","author":"RL Robinson","year":"2000","unstructured":"Robinson RL, Swindle RW. Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors. J Womens Health Gend Based Med. 2000;9:757\u201368.","journal-title":"J Womens Health Gend Based Med"},{"key":"18_CR7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/030144699282741","volume":"26","author":"P Montero","year":"1999","unstructured":"Montero P, Bernis C, Loukid M, et al. Characteristics of menstrual cycles in Moroccan girls: prevalence of dysfunctions and associated behaviours. Ann Hum Biol. 1999;26:243\u20139.","journal-title":"Ann Hum Biol"},{"key":"18_CR8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0197-0070(91)90014-D","volume":"12","author":"D Shye","year":"1991","unstructured":"Shye D, Jaffe B. Prevalence and correlates of perimenstrual symptoms: a study of Israeli teenage girls. J Adolesc Health. 1991;12:217\u201324.","journal-title":"J Adolesc Health"},{"key":"18_CR9","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1447-0756.2010.01505.x","volume":"37","author":"A Dosdzol","year":"2011","unstructured":"Dosdzol A, Nowosielski K, Skrzypulec V, et al. Premenstrual disorders in Polish adolescents girls: prevalence and risk factors. J Obstet Gynaecol Res. 2011;37:1216\u201321.","journal-title":"J Obstet Gynaecol Res"},{"key":"18_CR10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jpag.2011.07.009","volume":"24","author":"O Ogebe","year":"2011","unstructured":"Ogebe O, Abdulmalik J, Bello-Mojeed MA, et al. A comparison of the prevalence of premenstrual dysphoric disorder and comorbidities among adolescents in the United States of America and Nigeria. J Pediatr Adolesc Gynecol. 2011;24:397\u2013403.","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"18_CR11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00737-010-0202-2","volume":"14","author":"M Steiner","year":"2011","unstructured":"Steiner M, Peer M, Palova E, et al. The premenstrual symptoms screening tool revised for adolescents (PSST-A): prevalence of severe PMS and premenstrual dysphoric disorder in adolescents. Arch Womens Ment Health. 2011;14:77\u201381.","journal-title":"Arch Womens Ment Health"},{"issue":"6","key":"18_CR12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00737-010-0181-3","volume":"13","author":"T Takeda","year":"2010","unstructured":"Takeda T, Koga S, Yaegashi N. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese high school students. Arch Womens Ment Health. 2010;13(6):535\u20137.","journal-title":"Arch Womens Ment Health"},{"issue":"10","key":"18_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-10-1","volume":"1","author":"M Delara","year":"2012","unstructured":"Delara M, Ghofranipur F, Azadfallah P, et al. Health related quality of life among adolescents with premenstrual disorders: a cross sectional study. Health Qual Life Outcomes. 2012;1(10):1.","journal-title":"Health Qual Life Outcomes"},{"key":"18_CR14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S0033291701004925","volume":"32","author":"HU Wittchen","year":"2002","unstructured":"Wittchen HU, Becker E, Lieb R, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med. 2002;32:119\u201332.","journal-title":"Psychol Med"},{"key":"18_CR15","first-page":"131","volume":"31","author":"M Rojnic Kuzman","year":"2007","unstructured":"Rojnic Kuzman M, Hotujac L. Premenstrual dysphoric disorder: a neglected diagnosis? Preliminary study on a sample of Croatian students. Coll Antropol. 2007;31:131\u20137.","journal-title":"Coll Antropol"},{"issue":"6","key":"18_CR16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jpag.2010.04.001","volume":"23","author":"TO Nwankwo","year":"2010","unstructured":"Nwankwo TO, Aniebue UU, Aniebue PN. Menstrual disorders in adolescent school girls in Enugu. Nigeria. J Pediatr Adolesc Gynecol. 2010;23(6):358\u201363.","journal-title":"Nigeria. J Pediatr Adolesc Gynecol"},{"key":"18_CR17","first-page":"289","volume":"53","author":"KA Yonkers","year":"1992","unstructured":"Yonkers KA, White K. Premenstrual exacerbation of depression: one process or two? J Clin Psychiatry. 1992;53:289\u201392.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl. 15","key":"18_CR18","first-page":"19","volume":"58","author":"KA Yonkers","year":"1997","unstructured":"Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry. 1997;58(Suppl. 15):19\u201325.","journal-title":"J Clin Psychiatry"},{"key":"18_CR19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.15288\/jsa.2004.65.464","volume":"65","author":"BL Perry","year":"2004","unstructured":"Perry BL, Miles D, Burruss K, et al. Premenstrual symptomatology and alcohol consumption in college women. J Stud Alcohol. 2004;65:464\u20138.","journal-title":"J Stud Alcohol"},{"key":"18_CR20","first-page":"431","volume":"62","author":"J Sein Anand","year":"2005","unstructured":"Sein Anand J, Chodorowski Z, Ciechanowicz R, et al. The relationship between suicidal attempts and menstrual cycle in women. Przegl Lek. 2005;62:431\u20133.","journal-title":"Przegl Lek"},{"key":"18_CR21","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/01.chi.0000135624.89971.d1","volume":"43","author":"DO Lee","year":"2004","unstructured":"Lee DO. Menstrually related self-injurious behavior in adolescents with autism [letter]. J Am Acad Child Adolesc Psychiatry. 2004;43:1193.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"18_CR22","first-page":"869","volume":"47","author":"LK Lee","year":"2006","unstructured":"Lee LK, Chen PC, Lee KK, et al. Menstruation among adolescent girls in Malaysia: a cross-sectional school survey. Singap Med J. 2006;47:869\u201374.","journal-title":"Singap Med J"},{"issue":"3","key":"18_CR23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00737-003-0018-4","volume":"6","author":"M Steiner","year":"2006","unstructured":"Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health. 2006;6(3):203\u20139.","journal-title":"Arch Womens Ment Health"},{"key":"18_CR24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejogrb.2004.04.021","volume":"116","author":"O Derman","year":"2004","unstructured":"Derman O, Kanbur NO, Tokur TE, et al. Premenstrual syndrome and associated symptoms in adolescent girls. Eur J Obstet Gynecol Reprod Biol. 2004;116:201\u20136.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"18_CR25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1054-139X(97)00239-5","volume":"22","author":"CS Cleckner-Smith","year":"1998","unstructured":"Cleckner-Smith CS, Doughty AS, Grossman JA. Premenstrual symptoms: prevalence and severity in an adolescent sample. J Adolesc Health. 1998;22:403\u20138.","journal-title":"J Adolesc Health"},{"key":"18_CR26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jpag.2006.06.015","volume":"19","author":"M Vichnin","year":"2006","unstructured":"Vichnin M, Freeman EW, Lin H, et al. Premenstrual syndrome (PMS) in adolescents: severity and impairment. J Pediatr Adolesc Gynecol. 2006;19:397\u2013402.","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"18_CR27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/1596-3519.68354","volume":"9","author":"BA Issa","year":"2010","unstructured":"Issa BA, Yussuf AD, Olatinwo AW, et al. Premenstrual dysphoric disorder among medical students of a Nigerian university. Ann Afr Med. 2010;9:118\u201322.","journal-title":"Ann Afr Med"},{"key":"18_CR28","first-page":"39","volume":"15","author":"American College of Obstetricians and Gynecologists","year":"2000","unstructured":"American College of Obstetricians and Gynecologists. Premenstrual syndrome. ACOG Practice Bulletin. 2000;15:39\u201353.","journal-title":"ACOG Practice Bulletin"},{"key":"18_CR29","unstructured":"Royal College of Obstetricians and Gynecologists. Management of premenstrual syndrome green-top guidelines. No. 48. London: Royal College of Obstetricians and Gynecologists; 2007."},{"key":"18_CR30","unstructured":"American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders. 4th edn, text revision. Washington, DC: American Psychiatric Association; 2000."},{"issue":"1","key":"18_CR31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00737-010-0201-3","volume":"14","author":"PM O\u2019Brien","year":"2011","unstructured":"O\u2019Brien PM, B\u00e4ckstr\u00f6m T, Brown C, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health. 2011;14(1):13\u201321.","journal-title":"Arch Womens Ment Health"},{"key":"18_CR32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00006842-199509000-00007","volume":"57","author":"EW Freeman","year":"1995","unstructured":"Freeman EW, Schweizer E, Rickels K. Personality factors in women with premenstrual syndrome. Psychosom Med. 1995;57:453\u20139.","journal-title":"Psychosom Med"},{"key":"18_CR33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bpobgyn.2007.08.004","volume":"22","author":"PJ Sulak","year":"2008","unstructured":"Sulak PJ. Continuous oral contraception: changing times. Best Pract Res Clin Obstet Gynaecol. 2008;22:355\u201374.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"1","key":"18_CR34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00737-005-0103-y","volume":"9","author":"J Endicott","year":"2006","unstructured":"Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006;9(1):41\u20139.","journal-title":"Arch Womens Ment Health"},{"key":"18_CR35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jpag.2006.05.002","volume":"19","author":"AM Houston","year":"2006","unstructured":"Houston AM, Abraham A, Huang Z, et al. Knowledge, attitudes, and consequences of menstrual health in urban adolescent females. J Pediatr Adolesc Gynecol. 2006;19:271\u20135.","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"18_CR36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0165-0327(90)90126-S","volume":"20","author":"TB Pearlstein","year":"1990","unstructured":"Pearlstein TB, Frank E, Rivera-Tovar A, et al. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord. 1990;20:129\u201334.","journal-title":"J Affect Disord"},{"key":"18_CR37","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4088\/JCP.v66n0404","volume":"66","author":"J Labad","year":"2005","unstructured":"Labad J, Menchon JM, Alonso P, et al. Female reproductive cycle and obsessive\u2014compulsive disorder. J Clin Psychiatry. 2005;66:428\u201335. (quiz 546).","journal-title":"J Clin Psychiatry"},{"key":"18_CR38","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/01.nmd.0000244488.17025.0e","volume":"194","author":"AT Portella","year":"2006","unstructured":"Portella AT, Haaga DA, Rohan KJ. The association between seasonal and premenstrual symptoms is continuous and is not fully accounted for by depressive symptoms. J Nerv Ment Dis. 2006;194:833\u20137.","journal-title":"J Nerv Ment Dis"},{"key":"18_CR39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0197-0070(91)90455-U","volume":"12","author":"CA Wilson","year":"1991","unstructured":"Wilson CA, Turner CW, Keye WR Jr. Firstborn adolescent daughters and mothers with and without premenstrual syndrome: a comparison. J Adolesc Health. 1991;12:130\u20137.","journal-title":"J Adolesc Health"},{"key":"18_CR40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S0033291701004901","volume":"32","author":"S Treolar","year":"2002","unstructured":"Treolar S, Heath A, Martin N. Genetic and environmental influences on premenstrual symptoms in an Australian twin sample. Psychol Med. 2002;32:25\u201338.","journal-title":"Psychol Med"},{"key":"18_CR41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.162.4.481","volume":"162","author":"JT Condon","year":"1993","unstructured":"Condon JT. The premenstrual syndrome: a twin study. Br J Psychiatry. 1993;162:481\u20136.","journal-title":"Br J Psychiatry"},{"key":"18_CR42","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.4088\/JCP.v65n1004","volume":"65","author":"A Perkonigg","year":"2004","unstructured":"Perkonigg A, Yonkers KA, Pfister H, et al. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry. 2004;65:1314\u201322.","journal-title":"J Clin Psychiatry"},{"key":"18_CR43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/01612840600996281","volume":"28","author":"A Koci","year":"2007","unstructured":"Koci A, Strickland O. Relationship of adolescent physical and sexual abuse to perimenstrual symptoms (PMS) in adulthood. Issues Ment Health Nurs. 2007;28:75\u201387.","journal-title":"Issues Ment Health Nurs"},{"issue":"1","key":"18_CR44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/01443610400023049","volume":"26","author":"SW Masho","year":"2005","unstructured":"Masho SW, Adera T, South-Paul J. Obesity as a risk factor for premenstrual syndrome. J Psychosom Obstet Gynaecol. 2005;26(1):33\u20139.","journal-title":"J Psychosom Obstet Gynaecol"},{"issue":"Suppl. 1","key":"18_CR45","first-page":"132","volume":"3","author":"AJ Rapkin","year":"2006","unstructured":"Rapkin AJ, Mikacich JA. Premenstrual syndrome in adolescents: diagnosis and treatment. Pediatr Endocrinol Rev. 2006;3(Suppl. 1):132\u20137.","journal-title":"Pediatr Endocrinol Rev"},{"key":"18_CR46","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jpag.2011.03.009","volume":"24","author":"LP Wong","year":"2011","unstructured":"Wong LP. Premenstrual syndrome and dysmenorrhea: urban-rural and multiethnic differences in perception, impacts, and treatment seeking. J Pediatr Adolesc Gynecol. 2011;24:272\u20137.","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"18_CR47","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jpag.2011.05.010","volume":"24","author":"NK Chandraratne","year":"2011","unstructured":"Chandraratne NK, Gunawardena NS. Premenstrual syndrome: the experience from a sample of Sri Lankan adolescents. J Pediatr Adolesc Gynecol. 2011;24:304\u201310.","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"18_CR48","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/her\/14.6.817","volume":"14","author":"JP Chau","year":"1999","unstructured":"Chau JP, Chang AM. Effects of an educational programme on adolescents with premenstrual syndrome. Health Educ Res. 1999;14:817\u201330.","journal-title":"Health Educ Res"},{"key":"18_CR49","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/01674820209074672","volume":"23","author":"MS Hunter","year":"2002","unstructured":"Hunter MS, Ussher JM, Browne SJ, et al. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol. 2002;23:193\u20139.","journal-title":"J Psychosom Obstet Gynaecol"},{"key":"18_CR50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0022-3999(93)90079-U","volume":"37","author":"JF Steege","year":"1993","unstructured":"Steege JF, Blumenthal JA. The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J Psychosom Res. 1993;37:127\u201333.","journal-title":"J Psychosom Res"},{"key":"18_CR51","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/archinte.165.11.1246","volume":"165","author":"ER Bertone-Johnson","year":"2005","unstructured":"Bertone-Johnson ER, Hankinson SE, Bendich A, et al. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med. 2005;165:1246\u201352.","journal-title":"Arch Intern Med"},{"key":"18_CR52","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0002-9378(98)70377-1","volume":"179","author":"S Thys-Jacobs","year":"1998","unstructured":"Thys-Jacobs S, Starkey P, Bernstein D, et al. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol. 1998;179:444\u201352.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"18_CR53","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1028-4559(09)60271-0","volume":"48","author":"Z Ghanbari","year":"2009","unstructured":"Ghanbari Z, Haghollahi F, Shariat M, et al. Effects of calcium supplement therapy in women with premenstrual syndrome. Taiwan J Obstet Gynecol. 2009;48(2):124\u20139.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"18_CR54","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0002-9378(88)90765-X","volume":"158","author":"DR Rubinow","year":"1988","unstructured":"Rubinow DR, Hoban MC, Grover GN, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol. 1988;158:5\u201311.","journal-title":"Am J Obstet Gynecol"},{"key":"18_CR55","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM199801223380401","volume":"338","author":"PJ Schmidt","year":"1998","unstructured":"Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338:209\u201316.","journal-title":"N Engl J Med"},{"key":"18_CR56","unstructured":"YAZ (drospirenone and ethinyl estradiol) [prescribing information]. Montville: Berlex, Inc.; 2006."},{"key":"18_CR57","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0002-9378(03)00927-X","volume":"189","author":"H Joffee","year":"2003","unstructured":"Joffee H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol. 2003;189:1523\u201330.","journal-title":"Am J Obstet Gynecol"},{"key":"18_CR58","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0029-7844(99)00524-4","volume":"95","author":"PJ Sulak","year":"2000","unstructured":"Sulak PJ, Scow RD, Preece C. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261\u20136.","journal-title":"Obstet Gynecol"},{"key":"18_CR59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.contraception.2007.04.002","volume":"76","author":"T Greco","year":"2007","unstructured":"Greco T, Graham CA, Bancroft J, et al. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception. 2007;76:8\u201317.","journal-title":"Contraception"},{"key":"18_CR60","doi-asserted-by":"crossref","unstructured":"Lopez LM, Kaptein A, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2008; (1): CD006586.","DOI":"10.1002\/14651858.CD006586.pub2"},{"key":"18_CR61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0015-0282(99)00205-8","volume":"72","author":"H Sullivan","year":"1999","unstructured":"Sullivan H, Furniss H, Spona J, et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril. 1999;72:115\u201320.","journal-title":"Fertil Steril"},{"key":"18_CR62","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/01.AOG.0000175834.77215.2e","volume":"106","author":"KA Yonkers","year":"2005","unstructured":"Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492\u2013501.","journal-title":"Obstet Gynecol"},{"key":"18_CR63","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.contraception.2005.08.021","volume":"72","author":"TB Pearlstein","year":"2005","unstructured":"Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of pre-menstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72:414\u201321.","journal-title":"Contraception"},{"key":"18_CR64","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0010-7824(94)00015-O","volume":"51","author":"P Muhn","year":"1995","unstructured":"Muhn P, Krattenmacher R, Beier S, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception. 1995;51:99\u2013110.","journal-title":"Contraception"},{"key":"18_CR65","unstructured":"US FDA. FDA drug safety communication: safety review update on the possible increased risk of blood clots with birth control pills containing drospirenone. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm273021.htm . Accessed 26 Sep 2011."},{"issue":"3","key":"18_CR66","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1783\/147118910791749425","volume":"36","author":"RL Reid","year":"2010","unstructured":"Reid RL, Westhoff C, Mansour D, et al. Oral contraceptives and venous thromboembolism consensus opinion from an International workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care. 2010;36(3):117\u201322.","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"3","key":"18_CR67","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/01.AOG.0000279448.62221.a8","volume":"110","author":"JD Seeger","year":"2007","unstructured":"Seeger JD, Loughlin J, Eng PM, et al. Risk of thromboembolism in women taking ethinylestradiol\/drospirenone and other oral contraceptives. Obstet Gynecol. 2007;110(3):587\u201393.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"18_CR68","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.contraception.2006.12.019","volume":"75","author":"JC Dinger","year":"2007","unstructured":"Dinger JC, Heinemann LA, K\u00fchl-Habich D. The safety of drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75(5):334\u201354.","journal-title":"Contraception"},{"issue":"343","key":"18_CR69","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","volume":"25","author":"\u00d8 Lidegaard","year":"2011","unstructured":"Lidegaard \u00d8, Nielsen LH, Skovlund CW, Skjeldestad FE, L\u00f8kkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001\u20139. BMJ. 2011;25(343):d6423.","journal-title":"BMJ"},{"issue":"1","key":"18_CR70","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jfprhc-2011-100260","volume":"38","author":"J Dinger","year":"2012","unstructured":"Dinger J, Shapiro S. Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets. J Fam Plann Rerpod Health Care. 2012;38(1):2\u20136.","journal-title":"J Fam Plann Rerpod Health Care"},{"issue":"3","key":"18_CR71","first-page":"191","volume":"35","author":"L Manzoli","year":"2012","unstructured":"Manzoli L, De Vito C, Marzuillo C, et al. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf. 2012;35(3):191\u2013205.","journal-title":"Drug Saf"},{"issue":"5","key":"18_CR72","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.contraception.2011.09.010","volume":"85","author":"EW Freeman","year":"2012","unstructured":"Freeman EW, Halbreich U, Grugg GS, et al. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg\/ethinyl estradiol 20\u00a0mg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception. 2012;85(5):437\u201345.","journal-title":"Contraception"},{"issue":"342","key":"18_CR73","doi-asserted-by":"crossref","first-page":"d2994","DOI":"10.1136\/bmj.d2994","volume":"3","author":"S O\u2019Brien","year":"2011","unstructured":"O\u2019Brien S, Rapkin A, Dennerstein L, et al. Diagnosis and management of premenstrual disorders. BMJ. 2011;3(342):d2994.","journal-title":"BMJ"},{"issue":"2","key":"18_CR74","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/10673220902891836","volume":"17","author":"J Cunningham","year":"2009","unstructured":"Cunningham J, Yonkers KA, O\u2019Brien S, et al. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009;17(2):120\u201337.","journal-title":"Harv Rev Psychiatry"},{"key":"18_CR75","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jadohealth.2004.12.006","volume":"37","author":"TJ Silber","year":"2005","unstructured":"Silber TJ, Valadez-Meltzer A. Premenstrual dysphoric disorder in adolescents: case reports of treatment with fluoxetine and review of the literature. J Adolesc Health. 2005;37:518\u201325.","journal-title":"J Adolesc Health"},{"key":"18_CR76","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM199506083322301","volume":"332","author":"M Steiner","year":"1995","unstructured":"Steiner M, Steinberg S, Steward D, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med. 1995;332:1529\u201334.","journal-title":"N Engl J Med"},{"key":"18_CR77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004714-199902000-00002","volume":"19","author":"EW Freeman","year":"1999","unstructured":"Freeman EW, Rickels K, Arredondo F, et al. Full-or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol. 1999;19:3\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"18_CR78","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4088\/JCP.v58n0905","volume":"58","author":"U Halbreich","year":"1997","unstructured":"Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry. 1997;58:399\u2013402.","journal-title":"J Clin Psychiatry"},{"key":"18_CR79","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ajog.2005.01.021","volume":"193","author":"M Steiner","year":"2005","unstructured":"Steiner M, Hirschberg AL, Bergeron R, et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol. 2005;193:352\u201360.","journal-title":"Am J Obstet Gynecol"},{"key":"18_CR80","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00004714-199810000-00007","volume":"18","author":"I Wikander","year":"1998","unstructured":"Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 1998;18:390\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"18_CR81","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0029-7844(01)01530-7","volume":"98","author":"EW Freeman","year":"2001","unstructured":"Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2001;98:737\u201344.","journal-title":"Obstet Gynecol"},{"key":"18_CR82","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00004714-199708000-00004","volume":"17","author":"TB Pearlstein","year":"1997","unstructured":"Pearlstein TB, Stone AB, Lund SA, et al. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol. 1997;17:261\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"18_CR83","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/jama.1997.03550120043031","volume":"278","author":"KA Yonkers","year":"1997","unstructured":"Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. JAMA. 1997;278:983\u20138.","journal-title":"JAMA"},{"key":"18_CR84","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.psy.0000140005.94790.9c","volume":"66","author":"LS Cohen","year":"2004","unstructured":"Cohen LS, Soares CN, Yonkers KA, et al. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med. 2004;66:707\u201313.","journal-title":"Psychosom Med"},{"key":"18_CR85","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0029-7844(02)02326-8","volume":"100","author":"U Halbreich","year":"2002","unstructured":"Halbreich U, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2002;100:1219\u201329.","journal-title":"Obstet Gynecol"},{"key":"18_CR86","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4088\/JCP.v67n1020","volume":"67","author":"SG Kornstein","year":"2006","unstructured":"Kornstein SG, Pearlstein TB, Fayyad R, et al. Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J Clin Psychiatry. 2006;67:1624\u201332.","journal-title":"J Clin Psychiatry"},{"key":"18_CR87","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00737-002-0162-2","volume":"6","author":"M Steiner","year":"2003","unstructured":"Steiner M, Brown E, Trzepacz P, et al. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch Womens Ment Health. 2003;6:71\u20137.","journal-title":"Arch Womens Ment Health"},{"issue":"3","key":"18_CR88","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00737-007-0181-0","volume":"10","author":"LN Ravindran","year":"2007","unstructured":"Ravindran LN, Woods SA, Steiner M, et al. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series. Arch Womens Ment Health. 2007;10(3):125\u20137.","journal-title":"Arch Womens Ment Health"},{"issue":"6","key":"18_CR89","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/AOG.0b013e318236edf2","volume":"118","author":"EW Freeman","year":"2011","unstructured":"Freeman EW, Sammel MD, Lin H, et al. Clinical subtypes of premenstrual syndrome and responses to sertaline treatment. Obstet Gynecol. 2011;118(6):1293\u2013300.","journal-title":"Obstet Gynecol"},{"key":"18_CR90","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1067\/mob.2003.207","volume":"188","author":"T Pearlstein","year":"2003","unstructured":"Pearlstein T, Joliat MJ, Brown EB, et al. Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment. Am J Obstet Gynecol. 2003;188:887\u201395.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"18_CR91","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajog.2012.02.009","volume":"207","author":"G Koren","year":"2012","unstructured":"Koren G, Nordeng H. Antidepressant risk during pregnancy: the benefit-risk ratio. Am J Obstet Gynecol. 2012;207(3):157\u201363.","journal-title":"Am J Obstet Gynecol"},{"key":"18_CR92","doi-asserted-by":"crossref","unstructured":"Hetrick S, Merry S, McKenzie J, et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2007; (3): CD004851.","DOI":"10.1002\/14651858.CD004851.pub2"},{"key":"18_CR93","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jpag.2006.09.014","volume":"20","author":"MM Nur","year":"2007","unstructured":"Nur MM, Romano ME, Siqueira LM. Premenstrual dysphoric disorder in an adolescent female: a case report of an adolescent with PMDD treated successfully with luteal phase dosing of fluoxetine 20\u00a0mg. J Pediatr Adolesc Gynecol. 2007;20:201\u20134.","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"18_CR94","unstructured":"US FDA, Center for Drug Evaluation and Research. Antidepressant use in children, adolescents, and adults. 2008. http:\/\/www.fda.gov\/cder\/ . Accessed 1 Mar 2013."},{"key":"18_CR95","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1176\/appi.ajp.163.11.1898","volume":"163","author":"RD Gibbons","year":"2006","unstructured":"Gibbons RD, Hur K, Bhaumik DK, et al. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry. 2006;163:1898\u2013904.","journal-title":"Am J Psychiatry"},{"key":"18_CR96","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/appi.ajp.2007.07030454","volume":"164","author":"RD Gibbons","year":"2007","unstructured":"Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators\u2019 suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007;164:1356\u201363.","journal-title":"Am J Psychiatry"},{"key":"18_CR97","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.yapd.2006.04.008","volume":"53","author":"B Jackson","year":"2006","unstructured":"Jackson B, Lurie S. Adolescent depression: challenges and opportunities: a review and current recommendations for clinical practice. Adv Pediatr. 2006;53:111\u201363.","journal-title":"Adv Pediatr"},{"key":"18_CR98","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1744-6171.2005.00015.x","volume":"18","author":"L Scahill","year":"2005","unstructured":"Scahill L, Hamrin V, Pachler ME. The use of selective serotonin reuptake inhibitors in children and adolescents with major depression. J Child Adolesc Psychiatr Nurs. 2005;18:86\u20139.","journal-title":"J Child Adolesc Psychiatr Nurs"},{"key":"18_CR99","first-page":"1005","volume":"33","author":"L Rowe","year":"2004","unstructured":"Rowe L, Tonge B, Melvin G. When should GPs prescribe SSRIs for adolescent depression? Aust Fam Physician. 2004;33:1005\u20138.","journal-title":"Aust Fam Physician"},{"issue":"1","key":"18_CR100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clinthera.2011.11.024","volume":"34","author":"HD Anderson","year":"2012","unstructured":"Anderson HD, Pace WD, Libby AM, et al. Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study. Clin Ther. 2012;34(1):113\u201323.","journal-title":"Clin Ther"},{"key":"18_CR101","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1471-0528.2004.00135.x","volume":"111","author":"KM Wyatt","year":"2004","unstructured":"Wyatt KM, Dimmock PW, Ismail KM, et al. The effectiveness of GnRHa with and without \u201cadd-back\u201d therapy in treating premenstrual syndrome: a meta analysis. BJOG. 2004;111:585\u201393.","journal-title":"BJOG"},{"key":"18_CR102","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0015-0282(16)57053-8","volume":"62","author":"G Mezrow","year":"1994","unstructured":"Mezrow G, Shoupe D, Spicer D, et al. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril. 1994;62:932\u20137.","journal-title":"Fertil Steril"},{"key":"18_CR103","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0140-6736(89)90784-8","volume":"2","author":"NR Watson","year":"1989","unstructured":"Watson NR, Studd JW, Sawas M, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet. 1989;2:730\u20132.","journal-title":"Lancet"},{"key":"18_CR104","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0165-1781(99)00043-8","volume":"86","author":"RW Lam","year":"1999","unstructured":"Lam RW, Carter D, Misri S, et al. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res. 1999;86:185\u201392.","journal-title":"Psychiatry Res"},{"key":"18_CR105","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1067\/mob.2003.403","volume":"188","author":"A Girman","year":"2003","unstructured":"Girman A, Lee R, Kligler B. An integrative medicine approach to premenstrual syndrome. Am J Obstet Gynecol. 2003;188:S56\u201365.","journal-title":"Am J Obstet Gynecol"},{"key":"18_CR106","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s004040000123","volume":"264","author":"D Berger","year":"2000","unstructured":"Berger D, Schaffner W, Schrader E, et al. Efficacy of Vitex agnus castus L extract Ze 440 in patients with premenstrual syndrome (PMS). Arch Gynecol Obstet. 2000;264:150\u20133.","journal-title":"Arch Gynecol Obstet"},{"key":"18_CR107","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/bmj.322.7279.134","volume":"322","author":"R Schellenberg","year":"2001","unstructured":"Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001;322:134\u20137.","journal-title":"BMJ"},{"issue":"3","key":"18_CR108","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/11530120-000000000-00000","volume":"24","author":"S Canning","year":"2010","unstructured":"Canning S, Waterman M, Orsi N, et al. The efficacy of Hypericum perforatum (St. John\u2019s wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24(3):207\u201325.","journal-title":"CNS Drugs"},{"key":"18_CR109","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1089\/acm.2004.10.925","volume":"10","author":"SM Hicks","year":"2004","unstructured":"Hicks SM, Walker AF, Gallagher J, et al. The significance of \u201cnonsignificance\u201d in randomized controlled studies: a discussion inspired by a double-blinded study on St. John\u2019s Wort (Hypericum perforatum I). for premenstrual symptoms. J Altern Complement Med. 2004;10:925\u201332.","journal-title":"J Altern Complement Med"},{"key":"18_CR110","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1185\/03007998709112403","volume":"10","author":"ID Vellacott","year":"1987","unstructured":"Vellacott ID, Shroff NE, Pearce MY, et al. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr Med Res Opin. 1987;10:450\u20136.","journal-title":"Curr Med Res Opin"},{"key":"18_CR111","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3109\/00016349509021201","volume":"74","author":"M Wang","year":"1995","unstructured":"Wang M, Hammarback S, Lindhe BA, et al. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand. 1995;74:803\u20138.","journal-title":"Acta Obstet Gynecol Scand"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-013-0018-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-013-0018-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-013-0018-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T09:28:37Z","timestamp":1562837317000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-013-0018-4"}},"subtitle":["Diagnosis and Pharmacological Treatment"],"short-title":[],"issued":{"date-parts":[[2013,3,26]]},"references-count":111,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["18"],"URL":"https:\/\/doi.org\/10.1007\/s40272-013-0018-4","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,26]]}}}